Tiziana Life Sciences Ltd
tizianalifesciences.comWhat Do They Do?
Develops Foralumab, an experimental antibody treatment for multiple sclerosis, Alzheimer’s disease and other brain and nerve diseases.
20-F for FY2025, filed May 1, 2026We are a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company that specializes in the developing transformative therapies for…View ↗
Our lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis…View ↗
Advance the clinical development of intranasally-administered Foralumab for treatment of neurodegenerative diseases, particularly…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed May 1, 2026
How Are They Changing?
A narrower treatment focus
The earlier report described development across multiple sclerosis, Crohn’s disease, lung disease and cancer; the latest centers clinical work on intranasal Foralumab for neurodegenerative diseases, with other assets deprioritized.
20-F for FY2022, filed Apr 26, 2023 20-F for FY2025, filed May 1, 2026Our lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis…View ↗
As announced in 2022, all other assets have been temporarily deprioritized to focus resources on Tiziana’s lead asset, Foralumab.View ↗
Advance the clinical development of intranasally-administered Foralumab for treatment of neurodegenerative diseases, particularly…View ↗
Loading...
